Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Vyne Therapeutics Inc (VYNE) USD0.0001

Sell:$2.70 Buy:$2.71 Change: No change
Market closed |  Prices as at close on 26 July 2021 | Switch to live prices |
Sell:$2.70
Buy:$2.71
Change: No change
Market closed |  Prices as at close on 26 July 2021 | Switch to live prices |
Sell:$2.70
Buy:$2.71
Change: No change
Market closed |  Prices as at close on 26 July 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vyne Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the developing proprietary therapies in dermatology. The Company's products include AMZEEQ minocycline, is used for the treatment of inflammatory lesions of moderate-to-severe acne vulgaris in adults and patients nine years of age and older, and ZILXI minocycline, is used for the treatment of inflammatory lesions of rosacea in adults. Its product pipeline includes FCD105, is a proprietary topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris. In addition, it is also developing program for FMX114, which is a combination topical gel for the potential treatment of mild-to-moderate atopic dermatitis. The Company uses its proprietary Molecule Stabilizing Technology (MST) platform to develop FCD105.

Contact details

Address:
520 U.S. Highway 22, Suite 204
BRIDGEWATER
08807
United States
Telephone:
+1 (650) 4861416
Website:
https://vynetherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VYNE
ISIN:
US92941V2097
Market cap:
$138.75 million
Shares in issue:
51.39 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • David Domzalski
    President, Chief Executive Officer, Director
  • Tyler Zeronda
    Chief Financial Officer, Treasurer
  • Garrett Galley
    Chief Technology Officer
  • Iain Stuart
    Chief Scientific Officer
  • Mutya Harsch
    Chief Legal Officer, General Counsel, Secretary
  • Matthew Wiley
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.